In both phase 3 trials, onabotulinumtoxinA significantly improved platysma band severity at maximum contraction compared with placebo. The Food and Drug Administration (FDA) has approved Botox ® ...
Please provide your email address to receive an email when new articles are posted on . Results showed statistically significant improvement in platysma prominence after treatment with Botox Cosmetic ...
Please provide your email address to receive an email when new articles are posted on . Platysma prominence treatment with 26 to 36 units of onabotulinumtoxinA was well-tolerated and had a favorable ...
IRVINE, Calif., Oct. 18, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearance ...
–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309).–Results support onabotulinumtoxinA as a ...
Double board-certified facial plastic surgeon Dr. Benjamin C. Stong advances deep plane facelift surgery through comprehensive platysma release and resuspension designed to enhance neck contour and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results